Northwest BiotherapeuticsNWBO
13F holders, Q3 2024 (September 30)11holders −2
0new positions
2sold out
$0.32avg. 13F price*
At the end of Q3 2024, 11 institutions reported holding Northwest Biotherapeutics (NWBO) in their 13F filings, down 2 from Q2 2024. 0 opened new positions and 2 sold out. The largest holders were Moloney Securities Asset Management, LLC ($148K), Opus Capital Group, LLC ($19K) and Williams Jones Wealth Management, LLC. ($11K).
- Company
- Northwest Biotherapeutics
- Filed as
- NW Biotherapeutics (Q3 2024)
- CUSIP
- 66737P600
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 2 | $22K |
All 13F filers, Q2 2024 → Q3 2024: 37,905 shares bought and 52,418 shares sold, net −14,513 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Moloney Securities Asset Management, LLC | 0.02% | Add +8.9% | 462,215 | $148K |
| Opus Capital Group, LLC | 0.00% | No change | 60,150 | $19K |
| Williams Jones Wealth Management, LLC. | 0.00% | No change | 35,000 | $11K |
| Ethos Financial Group, LLC | 0.00% | No change | 23,700 | $8K |
| MAI Capital Management | 0.00% | No change | 20,000 | $6K |
| Lee Danner & Bass Inc. | 0.00% | No change | 20,000 | $6K |
| AlphaMark Advisors, LLC | 0.00% | No change | 14,007 | $4K |
| KLCM Advisors, Inc. | 0.00% | No change | 10,000 | $3K |
| Advisors Management Group Inc. | 0.00% | No change | 10,270 | $3K |
| Hantz Financial Services, Inc. | 0.00% | No change | 250 | $0 |
| Coston, McIsaac & Partners | 0.00% | No change | 1,000 | $0 |
"% of holder's portfolio" is NWBO's weight in each manager's 13F, not the share of Northwest Biotherapeutics the manager owns.